

# Anne Vincent-Salomon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/361075/publications.pdf>

Version: 2024-02-01

120  
papers

12,413  
citations

47006

47  
h-index

30922

102  
g-index

127  
all docs

127  
docs citations

127  
times ranked

19776  
citing authors

#	ARTICLE	IF	CITATIONS
1	The alternative RelB NF- $\kappa$ B subunit is a novel critical player in diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 384-398.	1.4	29
2	Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. <i>European Journal of Medical Genetics</i> , 2022, 65, 104385.	1.3	6
3	Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer. <i>Cancers</i> , 2022, 14, 295.	3.7	5
4	Value of the loss of heterozygosity to BRCA1 variant classification. <i>Npj Breast Cancer</i> , 2022, 8, 9.	5.2	2
5	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). <i>Cancer Research</i> , 2022, 82, P1-02-09-P1-02-09.	0.9	0
6	Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-18-P3-09-18.	0.9	0
7	Abstract PD11-04: A multi-feature AI-based solution for cancer diagnosis in breast biopsies: A prospective blinded multi-site clinical study. <i>Cancer Research</i> , 2022, 82, PD11-04-PD11-04.	0.9	0
8	Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes. <i>OncImmunity</i> , 2022, 11, 2057396.	4.6	9
9	Tissue-resident FOLR2+ macrophages associate with CD8+ T $\alpha$ cell infiltration in human breast cancer. <i>Cell</i> , 2022, 185, 1189-1207.e25.	28.9	166
10	Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 191-205.	3.0	19
11	Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS. <i>Analytical Chemistry</i> , 2022, 94, 6297-6303.	6.5	13
12	H3K27me3 conditions chemotolerance in triple-negative breast cancer. <i>Nature Genetics</i> , 2022, 54, 459-468.	21.4	44
13	Kindlin-1 modulates the EGFR pathway and predicts sensitivity to EGFR inhibitors across cancer types. <i>Clinical and Translational Medicine</i> , 2022, 12, e813.	4.0	0
14	Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals. <i>Cancers</i> , 2022, 14, 2114.	3.7	2
15	Safety and tolerability of olaparib combined with breast radiotherapy in patients with triple-negative breast cancer: Final results of the RADIOPARP phase 1 trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 534-534.	1.6	0
16	Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression. <i>Modern Pathology</i> , 2022, 35, 1624-1635.	5.5	3
17	Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 146-153.	6.3	31
18	Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial. <i>Molecular Oncology</i> , 2021, 15, 104-115.	4.6	10

#	ARTICLE	IF	CITATIONS
19	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , 2021, 15, 1024-1039.	4.6	21
20	PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. <i>Cancers</i> , 2021, 13, 746.	3.7	9
21	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. <i>Npj Breast Cancer</i> , 2021, 7, 41.	5.2	33
22	Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance. <i>Oncogene</i> , 2021, 40, 4019-4032.	5.9	19
23	The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 69.	5.2	7
24	A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial. <i>Npj Precision Oncology</i> , 2021, 5, 59.	5.4	16
25	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. <i>Cancers</i> , 2021, 13, 3695.	3.7	35
26	Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up. <i>Current Opinion in Oncology</i> , 2021, 33, 420-431.	2.4	8
27	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. <i>Modern Pathology</i> , 2021, 34, 2130-2140.	5.5	14
28	HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. <i>Journal of Hematology and Oncology</i> , 2021, 14, 143.	17.0	7
29	Neoadjuvant Concurrent Radiotherapy and Chemotherapy in Early Breast Cancer Patients: Long-Term Results of a Prospective Phase II Trial. <i>Cancers</i> , 2021, 13, 5107.	3.7	2
30	CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer. <i>Cancers</i> , 2021, 13, 5878.	3.7	17
31	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. <i>Modern Pathology</i> , 2020, 33, 354-366.	5.5	25
32	A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 76.	5.0	41
33	PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. <i>Nature Communications</i> , 2020, 11, 4053.	12.8	77
34	A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1481-1489.	6.4	4
35	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6254-6265.	7.0	22
36	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. <i>Journal of Clinical Pathology</i> , 2020, , jclinpath-2020-207052.	2.0	5

#	ARTICLE	IF	CITATIONS
37	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2198-2207.	5.5	21
38	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106
39	Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. <i>Cancer Discovery</i> , 2020, 10, 1330-1351.	9.4	424
40	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
41	Transcriptional and Functional Analysis of CD1c+ Human Dendritic Cells Identifies a CD163+ Subset Priming CD8+CD103+ T Cells. <i>Immunity</i> , 2020, 53, 335-352.e8.	14.3	206
42	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	86
43	AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells. <i>Cells</i> , 2020, 9, 247.	4.1	25
44	Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. <i>Nature Communications</i> , 2020, 11, 404.	12.8	230
45	ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. <i>Bioinformatics</i> , 2020, 36, 3888-3889.	4.1	35
46	Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 6731-6741.	7.0	53
47	The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019, 29, 356-366.	5.5	85
48	HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports. <i>BMC Cancer</i> , 2019, 19, 375.	2.6	17
49	ESR1 mutations in metastatic lobular breast cancer patients. <i>Npj Breast Cancer</i> , 2019, 5, 9.	5.2	26
50	Pan-TRK Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1693-1700.	3.7	49
51	Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 389-396.	0.8	14
52	Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 573-583.	2.5	13
53	A New Transcutaneous Method for Breast Cancer Detection with Dogs. <i>Oncology</i> , 2019, 96, 110-113.	1.9	12
54	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2605-2615.	7.0	45

#	ARTICLE	IF	CITATIONS
55	Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. <i>Cancer Cell</i> , 2018, 33, 463-479.e10.	16.8	1,074
56	Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 295-304.	2.5	54
57	miR200-regulated CXCL12 <sup>hi</sup> promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. <i>Nature Communications</i> , 2018, 9, 1056.	12.8	188
58	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. <i>Modern Pathology</i> , 2018, 31, 68-82.	5.5	58
59	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018, 72, 1075-1083.	2.9	25
60	Distinct expression profiles and functions of Kindlins in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 281.	8.6	14
61	Emerging Role of IL-4-Induced Gene 1 as a Prognostic Biomarker Affecting the Local T-Cell Response in Human Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2625-2634.	0.7	26
62	VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX. <i>BMC Biology</i> , 2018, 16, 109.	3.8	26
63	The Dilemma of HER2 Double-equivocal Breast Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1190-1200.	3.7	20
64	High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. <i>Histopathology</i> , 2018, 73, 273-283.	2.9	33
65	Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function. <i>Oncogene</i> , 2018, 37, 6425-6441.	5.9	36
66	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5767-5771.	7.0	68
67	Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. <i>Nature Immunology</i> , 2018, 19, 885-897.	14.5	152
68	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. <i>American Journal of Pathology</i> , 2018, 188, 2378-2391.	3.8	12
69	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. <i>Clinical Cancer Research</i> , 2017, 23, 3859-3870.	7.0	129
70	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 4402-4415.	7.0	91
71	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. <i>Nature Medicine</i> , 2017, 23, 517-525.	30.7	769
72	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. <i>Npj Breast Cancer</i> , 2017, 3, 48.	5.2	63

#	ARTICLE	IF	CITATIONS
73	Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. <i>PLoS ONE</i> , 2017, 12, e0169962.	2.5	4
74	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. <i>Histopathology</i> , 2016, 68, 262-271.	2.9	22
75	Chronic oxidative stress promotes H2 <sc>AX</sc> protein degradation and enhances chemosensitivity in breast cancer patients. <i>EMBO Molecular Medicine</i> , 2016, 8, 527-549.	6.9	126
76	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	27.8	1,760
77	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. <i>Modern Pathology</i> , 2016, 29, 1292-1305.	5.5	68
78	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. <i>Histopathology</i> , 2016, 68, 45-56.	2.9	37
79	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016, 7, 12910.	12.8	119
80	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv362.	6.3	71
81	Satellite in transit metastases in rapidly fatal conjunctival melanoma: implications for angiotropism and extravascular migratory metastasis (description of a murine model for conjunctival melanoma). <i>Pathology</i> , 2016, 48, 166-176.	0.6	14
82	<i>ERBB2</i> mutations associated with solid variant of high-grade invasive lobular breast carcinomas. <i>Oncotarget</i> , 2016, 7, 73337-73346.	1.8	34
83	The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. <i>Genome Research</i> , 2015, 25, 488-503.	5.5	106
84	Breast Cancer Cellâ€“Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. <i>Cancer Research</i> , 2015, 75, 2775-2787.	0.9	49
85	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824.	5.5	69
86	ARF6â€“JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion. <i>Journal of Cell Biology</i> , 2015, 211, 339-358.	5.2	126
87	Genomic landscape of adenoid cystic carcinoma of the breast. <i>Journal of Pathology</i> , 2015, 237, 179-189.	4.5	133
88	Unraveling the Role of Huntingtin in Breast Cancer Metastasis. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv208.	6.3	32
89	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. <i>Genome Biology</i> , 2015, 16, 107.	8.8	109
90	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1324-1334.	10.7	897

#	ARTICLE	IF	CITATIONS
91	Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. <i>Modern Pathology</i> , 2015, 28, 340-351.	5.5	80
92	First description of a sporadic breast cancer in a woman with BRCA1 germline mutation. <i>Oncotarget</i> , 2015, 6, 35616-35624.	1.8	9
93	Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts. <i>PLoS ONE</i> , 2014, 9, e104227.	2.5	10
94	Control of MT1-MMP transport by atypical PKC during breast-cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1872-9.	7.1	76
95	MSC-Regulated MicroRNAs Converge on the Transcription Factor FOXP2 and Promote Breast Cancer Metastasis. <i>Cell Stem Cell</i> , 2014, 15, 762-774.	11.1	155
96	Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. <i>Molecular Oncology</i> , 2014, 8, 1588-1602.	4.6	49
97	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2013, 37, e1-e11.	3.7	137
98	Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas. <i>PLoS ONE</i> , 2013, 8, e76496.	2.5	16
99	Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with <i>BRCA1/2</i> Inactivation. <i>Cancer Research</i> , 2012, 72, 5454-5462.	0.9	515
100	Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17460-17465.	7.1	188
101	High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients. <i>Breast</i> , 2012, 21, 380-383.	2.2	13
102	Oxidative stress promotes myofibroblast differentiation and tumour spreading. <i>EMBO Molecular Medicine</i> , 2010, 2, 211-230.	6.9	261
103	Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma. <i>European Journal of Cancer</i> , 2009, 45, 1979-1986.	2.8	9
104	Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma <i>In situ</i> of the Breast. <i>Clinical Cancer Research</i> , 2008, 14, 1956-1965.	7.0	148
105	A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays. <i>Clinical Cancer Research</i> , 2007, 13, 3989-3998.	7.0	364
106	Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. <i>Breast Cancer Research</i> , 2007, 9, R24.	5.0	154
107	High Prevalence of <i>Helicobacter pylori</i> (Hp) Infection in Ocular Adnexal Lymphoma (OAL).. <i>Blood</i> , 2006, 108, 4597-4597.	1.4	0
108	Breast Non Hodgkin's Lymphoma (NHL): A Large Monocentric Study of Initial Characteristics, Natural History, and Prognostic Factors.. <i>Blood</i> , 2006, 108, 2455-2455.	1.4	20

#	ARTICLE	IF	CITATIONS
109	Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. <i>European Journal of Cancer</i> , 2004, 40, 1502-1508.	2.8	75
110	Host microenvironment in breast cancer development: Epithelialâ€mesenchymal transition in breast cancer development. <i>Breast Cancer Research</i> , 2003, 5, 101-6.	5.0	199
111	HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. <i>Cancer</i> , 2002, 94, 2169-2173.	4.1	98
112	Primary Chemotherapy for Operable Breast Cancer: Incidence and Prognostic Significance of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery. <i>Journal of Clinical Oncology</i> , 2001, 19, 3828-3835.	1.6	141
113	Diagnostic accuracy of sonography and combined sonographic assessment and sonographically guided cytology in nonpalpable solid breast lesions. <i>Journal of Clinical Ultrasound</i> , 2000, 28, 387-398.	0.8	13
114	T-Cell Infiltrate After Monoclonal Anti-CD20 Antibody Therapy for B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 37, 387-391.	1.3	2
115	Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma. <i>Modern Pathology</i> , 2000, 13, 1238-1243.	5.5	103
116	Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185HER2/neu protein expression in breast cancer drill biopsies. , 1999, 83, 157-161.		23
117	Quantitative PCR analysis of cerb B2 (HER2/neu) gene amplification and comparison with p185HER2neu protein expression in breast cancer drill biopsies. <i>International Journal of Cancer</i> , 1999, 83, 157-161.	5.1	1
118	No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. , 1998, 79, 27-33.		139
119	Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. , 1996, 77, 113-120.		348
120	Decreased frequency of HLA-DRB 1*13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. , 1996, 69, 159-164.		74